康艾注射液联合紫杉醇、替吉奥、奥沙利铂化疗对进展期胃癌预后的影响

 目的 观察康艾注射液联合化疗对诱导型血红素氧合酶-1(Hemeoxygenase-1, HO-1)阳性进展期胃癌患者预后的影响。方法 将60例血红素氧合酶阳性进展期胃癌患者随机分为实验组和对照组,每组 30 例,实验组予以康艾注射液联合紫杉醇、替吉奥、奥沙利铂方案治疗,对照组应用紫杉醇、替吉奥、奥沙利铂方案化疗。4个周期化疗后进行疗效评价及HO-1检测。结果 实验组1年、2年生存率(75.2%、22.3%)均高于对照组(59.3%、15.4%),差异有统计学意义(P＜0.05)。KPS评分提高10分比例,实验组高于对照组,差异有统计学意义(P＜0.05)。结论 康艾注射液对HO-1阳性进展期胃癌有治疗作用,能抑制胃癌组织中HO-1的表达,减轻患者不良反应。

Effect of Kang Ai injection combined with paclitaxel,tegafur, oxaliplatin on prognosis of advanced gastric cancer

Objective To observe the effect of Kang Ai injection combined with chemotherapy on heme oxygenase 1 (HO-1), positive outcomes in patients with advanced gastric cancer. Methods Sixty patients with positive heme oxygenase and advanced gastric cancer by were randomly divided into study group and control group, 30 patients in each group. The study group received Kang Ai injection in combination with paclitaxel, tegafur, oxaliplatin. The control group took paclitaxel, tegafur, oxaliplatin. After four cycles of chemotherapy, curative effect evaluation and HO-1 was tested. Results In the study group, strong positive rate of HO-1(24.0%, 74.3%), 1 year survival rate (74.3%, 52.1%), and 2 year survival rate(20.2%, 11.0%)were higher those in the control group, KPS increased by more than 10 points(70%, 15%),the differences between the two groups had statistical significance(P＜0.05). Conclusions Kang Ai injection therapy for advanced gastric cancer can inhibit the expression of gastric cancer tissues HO-1, and reduce the side effects, improve the prognosis of patients, and prolong the survival period.